Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.63 |
| ▸ | NPY4R | P50391 | 8/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.63 |
| ▸ | NPY1R | P25929 | 6/20 | 0.63 |
| ▸ | TFPI | P10646 | 5/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.60 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.56 |
| ▸ | CALCR | P30988 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apidaecin SCHEMBL29380656 | 0.96 | NPY4R (0.67) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29458102 | 0.93 | NPY4R (0.62) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Apidaecin Ia SCHEMBL31694517 | 0.92 | F2 (0.58) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL18872896 | 0.88 | AGTR1 (0.68) | NPY2RNPY4RNPY5RNPY1RAGTR1 | |
| SCHEMBL29874441 | 0.88 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL18872894 | 0.87 | AGTR1 (0.68) | NPY2RNPY4RNPY5RNPY1RAGTR1 | |
| Drosocin SCHEMBL29539177 | 0.86 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29702111 | 0.84 | F2 (0.61) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL38662565 | 0.84 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Trv-120027 SCHEMBL29382211 | 0.84 | AGTR1 (0.73) | NPY2RNPY4RNPY5RNPY1RAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-RE50618-E1 | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same | PHARMAIN CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250256007-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CELLS | GELMEDIX INC (US) | 2025-08-14 | — | — | US | disclosed |
| WO-2025085609-A1 | ACRYLATED GELATIN POLYMER COMPOSITIONS COMPRISING CELLS | GELMEDIX, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4511075-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CELLS | Gelmedix, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240398958-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240374792-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4401802-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | Gelmedix, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118215511-A | GELMA polymer compositions and uses thereof | 盖尔梅迪克斯公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023205265-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CELLS | GELMEDIX, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023044389-A1 | GELMA POLYMER COMPOSITIONS COMPRISING CORTICOSTEROIDS | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044385-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11473104-B2 | Engineered phagemids | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-20220288273-A1 | OSTEOINDUCTIVE MODIFIED GELATIN HYDROGELS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-15 | — | — | US | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022076505-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | NPY2R 4275/4885NPY4R 4231/4885NPY5R 4217/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | NPY2R 4224/4885NPY4R 4239/4885NPY5R 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.